 comparison induction maintenance therapy acute nonlymphocytic leukemia childhood results Pediatric Oncology Group study fifty-six children acute nonlymphocytic leukemia ANLL Pediatric Oncology Group POG phase III trial induction continuation chemotherapies Induction therapy vincristine cytarabine dexamethasone VADx daunorubicin cytarabine thioguanine DAT complete remission CR rate DAT superior Postremission therapy standard two-cycle therapy intensive four-cycle regimen years Overall difference outcome patients continuation regimen overall complete continuous remission rate CCR induction/continuation therapy combination years SE years years Analysis clinical laboratory parameters differences induction responses DAT induction eventual disease-free survival subgroups patients four-cycle continuation therapy patients French-American-British FAB CCR patients years diagnosis